Source comparison
Cost Comparison: Real Numbers
Cost is a significant factor, and the range spans two orders of magnitude depending on the source. Egrifta SV (brand tesamorelin) ~$3,085/month Prescription required; insurance may cover for HIV indication Compounded tesamorelin $150-300/month Compounding phar
This comparison does not assign a generated winner or score.
- Cost is a significant factor, and the range spans two orders of magnitude depending on the source.
- Egrifta SV (brand tesamorelin)
- ~$3,085/month
- Prescription required; insurance may cover for HIV indication
- Compounded tesamorelin
- $150-300/month
- Compounding pharmacy; prescription required
- CJC-1295 with DAC
- Research compound; compounding pharmacy
- CJC-1295 no DAC
- $100-200/month
- Add ipamorelin cost ($100-200) for combination
- Brand Egrifta SV is prohibitively expensive for most non-HIV patients. Compounded tesamorelin costs roughly the same as compounded CJC-1295. The cost advantage of CJC-1295 no-DAC disappears when adding ipamorelin, which is the standard combination.
- For budget-conscious users, the decision between compounded tesamorelin and CJC-1295 with DAC is roughly equivalent in price. The decision then shifts to evidence quality (tesamorelin) versus dosing convenience (CJC-1295 DAC weekly injections).